An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy

Bhattacharjee A., Patil V.M. (2016): Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection. Turkiye Klinikleri J Biostat 8: 103-109.10.5336/biostatic.2016-51505Search in Google Scholar

Bhattacharjee A., Patil V.M. (2017): Determining an Optimum Biological Dose of a Metronomic chemotherapy. Journal of Data Science 15(1):77-94.10.6339/JDS.201701_15(1).0005Search in Google Scholar

Briasoulis E., Pappas P., Puozzo C., Tolis C., Fountzilas G., Dafni U. (2009): Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15: 6454-6461.10.1158/1078-0432.CCR-09-0970Search in Google Scholar

Cheung Y.K., Chappell R. (2000): Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56: 1177-1182.10.1111/j.0006-341X.2000.01177.xSearch in Google Scholar

DeVita V.T. Jr., Chu E. (2008): A history of cancer chemotherapy. Cancer Res 68: 8643-8653.10.1158/0008-5472.CAN-07-6611Search in Google Scholar

Golfinopoulos V., Salanti G., Pavlidis N., Ioannidis J.P.A. (2007): Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8: 898-911.10.1016/S1470-2045(07)70281-4Search in Google Scholar

Hanahan D., Bergers G., Bergsland E. (2000): Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047.10.1172/JCI987230084210772648Search in Google Scholar

Hobson B., Denekamp J. (1984): Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49: 405-413.10.1038/bjc.1984.6619767596201181Search in Google Scholar

Ilie M., Long E., Hofman V., Selva E., Bonnetaud C., Boyer J.(2014): Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer 110: 1236-1243.10.1038/bjc.2014.11395086324473396Search in Google Scholar

Kerbel R.S., Kamen B.A. (2004): The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.10.1038/nrc136915170445Search in Google Scholar

Kerbel R.S., Klement G., Pritchard K.I., Kamen B. (2002): Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13: 12-15.10.1093/annonc/mdf09311863092Search in Google Scholar

Kumar R., Jose J., Vishwakarma G.K., Bhattacharjee A. (2017): Alternative of clinical end point selection for metronomic studies. IJS Short Reports. Medknow Publications and Media Pvt. Ltd 2: 50.10.4103/ijssr.ijssr_10_17Search in Google Scholar

Marmé D., Fusenig N. (2007): Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy. Springer Science & Business Media.10.1007/978-3-540-33177-3Search in Google Scholar

Pantziarka P., Hutchinson L., André N., Benzekry S., Bertolini F., Bhattacharjee A. (2016): Next generation metronomic chemotherapy - Report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6- 8 May 2016, Mumbai. Ecancermedicalscience 10: 689.10.3332/ecancer.2016.689513032827994645Search in Google Scholar

Patil V.M., Noronha V., Joshi A., Muddu V.K., Dhumal S., Bhosale B.(2015): A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. Elsevier 51: 279-286.10.1016/j.oraloncology.2014.12.00225578869Search in Google Scholar

Saltz L.B. (2008): Progress in cancer care: the hope, the hype, and the gap between reality and perception. J Clin Oncol 26: 5020-5021.10.1200/JCO.2008.17.619818794538Search in Google Scholar

Scharovsky O.G., Mainetti L.E., Rozados VR. (2009): Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol. 16: 7-15.10.3747/co.v16i2.420266923119370174Search in Google Scholar

Schmid P., Schippinger W., Nitsch T., Huebner G., Heilmann V., Schultze W.(2005): Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23: 432-440.10.1200/JCO.2005.06.07215659490Search in Google Scholar

Skipper H.E., Schabel F.M. Jr, Mellett L.B., Montgomery J.A., Wilkoff L.J., Lloyd H.H. (1970): Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54: 431-450.Search in Google Scholar

Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico B., Ria R.(1999): Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94: 4143-4155.10.1182/blood.V94.12.4143Search in Google Scholar